Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, have demonstrated durable responses and improved survival in patients with advanced NSCLC [46]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.